• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma.

作者信息

Liu Shanshan, Zhou Hongwei, Xu Weiling, Jin Tao, Liang Xinyue, Zhao Xiaoxia, Dai Yun, Jin Fengyan

机构信息

Hematology Department, First Hospital of Jilin University, 71 Xinmin Street, Changchun, 130012, Jilin, China.

Laboratory of Cancer Precision Medicine, First Hospital of Jilin University, 519 Dongminzhu Street, Changchun, 130061, Jilin, China.

出版信息

Ann Hematol. 2023 Apr;102(4):967-969. doi: 10.1007/s00277-023-05120-w. Epub 2023 Feb 8.

DOI:10.1007/s00277-023-05120-w
PMID:36752844
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9907188/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a902/9907188/6f2680f606d9/277_2023_5120_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a902/9907188/6f2680f606d9/277_2023_5120_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a902/9907188/6f2680f606d9/277_2023_5120_Fig1_HTML.jpg

相似文献

1
Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma.达雷妥尤单抗治疗多发性骨髓瘤患者时出现的早期白质脑病。
Ann Hematol. 2023 Apr;102(4):967-969. doi: 10.1007/s00277-023-05120-w. Epub 2023 Feb 8.
2
Use of Daratumumab in Patients With Previously Treated Multiple Myeloma.达雷妥尤单抗在既往接受过治疗的多发性骨髓瘤患者中的应用。
J Clin Oncol. 2023 May 10;41(14):2668. doi: 10.1200/JCO.22.02850. Epub 2023 Mar 20.
3
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience.达雷妥尤单抗、来那度胺和地塞米松联合治疗复发/难治性骨髓瘤患者：单中心真实世界经验
Leuk Lymphoma. 2020 Dec;61(13):3255-3258. doi: 10.1080/10428194.2020.1802452. Epub 2020 Aug 10.
4
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.达雷妥尤单抗、来那度胺和地塞米松与来那度胺和地塞米松单独治疗新诊断多发性骨髓瘤（MAIA）的疗效比较：一项随机、开放标签、3 期临床试验的总生存结果。
Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13.
5
Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松用于新诊断的与多发性骨髓瘤相关的系统性轻链淀粉样变患者
Br J Haematol. 2022 Aug;198(3):e38-e41. doi: 10.1111/bjh.18234. Epub 2022 May 7.
6
Association of Daratumumab Use With Ocular Events in a Case Series of US Adults.达雷妥尤单抗使用与美国成人病例系列中眼部事件的关联。
JAMA Oncol. 2022 Aug 1;8(8):1209-1210. doi: 10.1001/jamaoncol.2022.1634.
7
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.达雷妥尤单抗联合来那度胺和地塞米松治疗初治多发性骨髓瘤。
N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.
8
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.达雷妥尤单抗联合来那度胺和地塞米松治疗复发或复发/难治性多发性骨髓瘤患者的持久疗效和耐受性（GEN503）：一项开放标签的1/2期研究的最终结果
Br J Haematol. 2019 Aug;186(3):e35-e39. doi: 10.1111/bjh.15879. Epub 2019 Mar 31.
9
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751.
10
Carfilzomib in combination with daratumumab in the management of relapsed multiple myeloma.卡非佐米联合达雷妥尤单抗治疗多发性骨髓瘤复发。
Future Oncol. 2021 Mar;17(9):993-998. doi: 10.2217/fon-2020-0907. Epub 2020 Dec 8.

引用本文的文献

1
Acute leukoencephalopathy associated with daratumumab treatment in POEMS syndrome: a case report.POEMS 综合征中与达雷妥尤单抗治疗相关的急性脑白质病：一例报告。
Front Immunol. 2024 Sep 26;15:1451693. doi: 10.3389/fimmu.2024.1451693. eCollection 2024.

本文引用的文献

1
Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma.基于达雷妥尤单抗治疗期间的白质脑病：两例多发性骨髓瘤患者的病例系列
Onco Targets Ther. 2022 Sep 6;15:953-962. doi: 10.2147/OTT.S365657. eCollection 2022.
2
Daratumumab in newly diagnosed MM - incorporating lessons learnt from CASSIOPEIA, MAIA and beyond.达雷妥尤单抗用于新诊断的多发性骨髓瘤——汲取CASSIOPEIA、MAIA等研究的经验教训
Nat Rev Clin Oncol. 2022 Jan;19(1):3-4. doi: 10.1038/s41571-021-00581-2.
3
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
嵌合抗原受体 T 细胞疗法治疗患者免疫相关不良反应的管理：ASCO 指南。
J Clin Oncol. 2021 Dec 10;39(35):3978-3992. doi: 10.1200/JCO.21.01992. Epub 2021 Nov 1.
4
CD38 in Neurodegeneration and Neuroinflammation.CD38 在神经变性和神经炎症中的作用。
Cells. 2020 Feb 18;9(2):471. doi: 10.3390/cells9020471.
5
Adulthood leukodystrophies.成人脑白质营养不良
Nat Rev Neurol. 2018 Feb;14(2):94-105. doi: 10.1038/nrneurol.2017.175. Epub 2018 Jan 5.
6
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.达雷妥尤单抗联合泊马度胺及地塞米松治疗复发和/或难治性多发性骨髓瘤
Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.
7
CD38 positively regulates postnatal development of astrocytes cell-autonomously and oligodendrocytes non-cell-autonomously.CD38以细胞自主方式正向调节星形胶质细胞的出生后发育，并以非细胞自主方式调节少突胶质细胞的出生后发育。
Glia. 2017 Jun;65(6):974-989. doi: 10.1002/glia.23139. Epub 2017 Mar 13.